Development of 11C-labeled CRANAD-102 for positron emission tomography imaging of soluble Aβ-species

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Development of 11C-labeled CRANAD-102 for positron emission tomography imaging of soluble Aβ-species. / Staudt, Markus; Shalgunov, Vladimir; Nedergaard, Maiken; Herth, Matthias M.

In: Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 66, No. 12, 2023, p. 393-399.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Staudt, M, Shalgunov, V, Nedergaard, M & Herth, MM 2023, 'Development of 11C-labeled CRANAD-102 for positron emission tomography imaging of soluble Aβ-species', Journal of Labelled Compounds and Radiopharmaceuticals, vol. 66, no. 12, pp. 393-399. https://doi.org/10.1002/jlcr.4060

APA

Staudt, M., Shalgunov, V., Nedergaard, M., & Herth, M. M. (2023). Development of 11C-labeled CRANAD-102 for positron emission tomography imaging of soluble Aβ-species. Journal of Labelled Compounds and Radiopharmaceuticals, 66(12), 393-399. https://doi.org/10.1002/jlcr.4060

Vancouver

Staudt M, Shalgunov V, Nedergaard M, Herth MM. Development of 11C-labeled CRANAD-102 for positron emission tomography imaging of soluble Aβ-species. Journal of Labelled Compounds and Radiopharmaceuticals. 2023;66(12):393-399. https://doi.org/10.1002/jlcr.4060

Author

Staudt, Markus ; Shalgunov, Vladimir ; Nedergaard, Maiken ; Herth, Matthias M. / Development of 11C-labeled CRANAD-102 for positron emission tomography imaging of soluble Aβ-species. In: Journal of Labelled Compounds and Radiopharmaceuticals. 2023 ; Vol. 66, No. 12. pp. 393-399.

Bibtex

@article{faf46dcfd365404e80eaba9235450f8b,
title = "Development of 11C-labeled CRANAD-102 for positron emission tomography imaging of soluble Aβ-species",
abstract = "CRANAD-102, a selective near-infrared fluorescent tracer targeting soluble amyloid-β (Aβ) species, has recently attracted attention due to its potential to be used as a diagnostic tool for early stages of Alzheimer's disease (AD). Development of a positron emission tomography (PET) tracer based on CRANAD-102 could as such allow to noninvasively study soluble and protofibrillar species of Aβ in humans. These soluble and protofibrillar species are thought to be responsible to cause AD. Within this work, we successfully 11C-labeled CRANAD-102 via a Suzuki–Miyaura reaction in a RCС of 48 ± 9%, with a RCP of >96% and a molar activity (Am) of 25 ± 7 GBq/μmol. Future studies have to be conducted to evaluate if [11C]CRANAD-102 can be used to detect soluble protofibrils in vivo and if [11C]CRANAD-102 can be used to detect AD earlier as possible with current diagnostics.",
keywords = "Alzheimer's disease, amyloid beta, carbon-11, radiolabeling, radiosynthesis",
author = "Markus Staudt and Vladimir Shalgunov and Maiken Nedergaard and Herth, {Matthias M.}",
note = "Funding information: Danmarks Frie Forskningsfond,Grant/Award Number: 2035-00077B",
year = "2023",
doi = "10.1002/jlcr.4060",
language = "English",
volume = "66",
pages = "393--399",
journal = "Journal of Labelled Compounds and Radiopharmaceuticals",
issn = "0362-4803",
publisher = "JohnWiley & Sons Ltd",
number = "12",

}

RIS

TY - JOUR

T1 - Development of 11C-labeled CRANAD-102 for positron emission tomography imaging of soluble Aβ-species

AU - Staudt, Markus

AU - Shalgunov, Vladimir

AU - Nedergaard, Maiken

AU - Herth, Matthias M.

N1 - Funding information: Danmarks Frie Forskningsfond,Grant/Award Number: 2035-00077B

PY - 2023

Y1 - 2023

N2 - CRANAD-102, a selective near-infrared fluorescent tracer targeting soluble amyloid-β (Aβ) species, has recently attracted attention due to its potential to be used as a diagnostic tool for early stages of Alzheimer's disease (AD). Development of a positron emission tomography (PET) tracer based on CRANAD-102 could as such allow to noninvasively study soluble and protofibrillar species of Aβ in humans. These soluble and protofibrillar species are thought to be responsible to cause AD. Within this work, we successfully 11C-labeled CRANAD-102 via a Suzuki–Miyaura reaction in a RCС of 48 ± 9%, with a RCP of >96% and a molar activity (Am) of 25 ± 7 GBq/μmol. Future studies have to be conducted to evaluate if [11C]CRANAD-102 can be used to detect soluble protofibrils in vivo and if [11C]CRANAD-102 can be used to detect AD earlier as possible with current diagnostics.

AB - CRANAD-102, a selective near-infrared fluorescent tracer targeting soluble amyloid-β (Aβ) species, has recently attracted attention due to its potential to be used as a diagnostic tool for early stages of Alzheimer's disease (AD). Development of a positron emission tomography (PET) tracer based on CRANAD-102 could as such allow to noninvasively study soluble and protofibrillar species of Aβ in humans. These soluble and protofibrillar species are thought to be responsible to cause AD. Within this work, we successfully 11C-labeled CRANAD-102 via a Suzuki–Miyaura reaction in a RCС of 48 ± 9%, with a RCP of >96% and a molar activity (Am) of 25 ± 7 GBq/μmol. Future studies have to be conducted to evaluate if [11C]CRANAD-102 can be used to detect soluble protofibrils in vivo and if [11C]CRANAD-102 can be used to detect AD earlier as possible with current diagnostics.

KW - Alzheimer's disease

KW - amyloid beta

KW - carbon-11

KW - radiolabeling

KW - radiosynthesis

U2 - 10.1002/jlcr.4060

DO - 10.1002/jlcr.4060

M3 - Journal article

C2 - 37653688

AN - SCOPUS:85169168693

VL - 66

SP - 393

EP - 399

JO - Journal of Labelled Compounds and Radiopharmaceuticals

JF - Journal of Labelled Compounds and Radiopharmaceuticals

SN - 0362-4803

IS - 12

ER -

ID: 366507564